Targeting Na+/K+‐ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma

Abstract

The multikinase inhibitor sorafenib is a first‐line drug for advanced hepatocellular carcinoma. The response to sorafenib varies among hepatocellular carcinoma patients and many of the responders suffer from reduced sensitivity after long‐term treatment. This study aims to explore a novel strategy to potentiate or maximize the anti‐hepatocellular carcinoma effects of sorafenib.